Skip to main content

Paul Langlie Martin, MD, PhD

Professor of Pediatrics
Chief, Division of Pediatric Blood and Marrow Transplantation
Member of the Duke Cancer Institute
Campus mail: 1400 Morrene Rd, Durham, NC 27705
Phone: (919) 668-1124
Email address: paul.martin@duke.edu

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.  

For most of my time at Duke I have concentrated on providing high quality care for high risk leukemia patients who require high intensity therapies, such as stem cell transplant and immunotherapy.  As a member of the Pediatric Transplant and Cellular Therapy Division I provide clinical care for these patients.  As a member of various cooperative groups and local PI for several drug trials, I have worked to provide better care and more specific therapies for the toxicities associated with stem cell transplant.  

I have also collaborated with the Pediatric Immunology Division to provide a life-saving therapy for a small group of patients with thymic dysfunction, which causes severe immunodeficiency.  Our clinical team now provides support during these patients hospital admissions for donor thymus tissue implantation.

Education and Training

  • Fellow, Pediatric Hematology/Oncology, Pediatrics, Yale University, 1989 - 1992
  • Resident, Pediatrics, Yale University, 1988 - 1989
  • Intern, Pediatrics, Yale University, 1987 - 1988
  • Ph.D., Washington University in St. Louis, 1987
  • M.D., Washington University in St. Louis, 1987

Publications

Chauvenet, Allen R., Paul L. Martin, Meenakshi Devidas, Stephen B. Linda, Beverly A. Bell, Joanne Kurtzberg, Jeanette Pullen, et al. “Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.” Blood 110, no. 4 (August 15, 2007): 1105–11. https://doi.org/10.1182/blood-2006-12-061689.

Full Text

Steinbach, William J., Rachel M. Addison, Lisa McLaughlin, Quincy Gerrald, Paul L. Martin, Timothy Driscoll, Christopher Bentsen, John R. Perfect, and Barbara D. Alexander. “Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients.” Pediatr Infect Dis J 26, no. 7 (July 2007): 558–64. https://doi.org/10.1097/INF.0b013e3180616cbb.

Full Text

Bradley, M., L. Baldinger, M. Bhatia, J. Garvin, D. George, E. Roman, P. Satwani, P. L. Martin, J. Kurtzberg, and M. S. Cairo. “A pilot study of myeloablative (MA) autologous stem Cell (Auto SCT) followed by reduced intensity (RI) allogeneic transplantation (AlloSCT) in children with relapsed/refractory(R/R) Hodgkin's disease (HD).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Scholars@Duke

Beam, Donald, Michele D. Poe, James M. Provenzale, Paul Szabolcs, Paul L. Martin, Vinod Prasad, Suhag Parikh, et al. “Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy.” Biol Blood Marrow Transplant 13, no. 6 (June 2007): 665–74. https://doi.org/10.1016/j.bbmt.2007.01.082.

Full Text

Parikh, S. H., P. L. Martin, V. K. Prasad, P. Szabolcs, T. A. Driscoll, and J. Kurtzberg. “173: Outcomes of matched related donor bone marrow transplantation in pediatric patients with myelodysplastic syndrome.” In Biology of Blood and Marrow Transplantation, 13:64–64. Elsevier BV, 2007. https://doi.org/10.1016/j.bbmt.2006.12.177.

Full Text

Szabolcs, P., P. L. Martin, S. Parikh, V. K. Prasad, R. Vinesett, M. L. Escolar, and J. Kurtzberg. “180: Chronic graft-versus host disease (GVHD) in children with mucopolysacharidoses (MPS) two years after unrelated donor umbilical cord blood transplantation (UCBT).” In Biology of Blood and Marrow Transplantation, 13:67–67. Elsevier BV, 2007. https://doi.org/10.1016/j.bbmt.2006.12.184.

Full Text

Baker, J. H., P. L. Martin, T. Driscoll, P. Szabolcs, J. Allison, K. Gurganus, G. Ciocci, S. Parikh, V. Prasad, and J. Kurtzberg. “377: Outcomes of pediatric patients transplanted a second time after experiencing graft failure with unrelated donor umbilical cord blood transplantation.” In Biology of Blood and Marrow Transplantation, 13:137–137. Elsevier BV, 2007. https://doi.org/10.1016/j.bbmt.2007.01.007.

Full Text

Parikh, S. H., A. Mendizabal, P. L. Martin, P. Szaboles, V. K. Prasad, T. A. Driscoll, and J. Kurtzberg. “Outcomes of unrelated umbilical cord blood transplantation in pediatric patients with myelodysplastic syndrome.” In Biology of Blood and Marrow Transplantation, 13:64–65. ELSEVIER SCIENCE INC, 2007.

Scholars@Duke

Lakshminarayanan, Sonali, Paul Szabolcs, Vinod Prasad, Suhag Parikh, Susan Wood, Gilbert Ciocci, Lauren Stafford, et al. “Acute Graft Versus Host Disease (GVHD) Is Increased in Patients Receiving Cyclosporine/Cellcept as Frontline Prophylaxis Against GVHD in Pediatric Patients Undergoing Allogeneic Stem Cell Transplantation.” In Blood, 108:2896–2896. American Society of Hematology, 2006. https://doi.org/10.1182/blood.v108.11.2896.2896.

Full Text

Richardson, Paul, R. J. Soiffer, J. H. Antin, Z. Jin, J. Kurtzberg, P. L. Martin, G. Steinbach, et al. “Defibrotide (DF) for the treatment of severe veno-occlusive disease (sVOD) and multi-organ failure (MOF) post SCT: Final results of a multi-center, randomized, dose-finding trial.” In Blood, 108:17A-18A. AMER SOC HEMATOLOGY, 2006.

Scholars@Duke

Pages